Peter Curtin

4.7k total citations · 2 hit papers
35 papers, 2.6k citations indexed

About

Peter Curtin is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Peter Curtin has authored 35 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 10 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Peter Curtin's work include Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Peter Curtin is often cited by papers focused on Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Peter Curtin collaborates with scholars based in United States, Italy and Australia. Peter Curtin's co-authors include Ashima Madan, Richard T. Maziarz, Yuet Wai Kan, Omer N. Koç, H. Kent Holland, Brenda Cooper, Annemarie Moseley, Mary J. Laughlin, Philip L. McCarthy and Andrea Bacigalupo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Peter Curtin

34 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients

2005 607 citations Hillard M. Lazarus, Omer N. Koç et al. Biology of Blood and Marrow Transplantation profile →
First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

2012 423 citations Paul J. Martin, J. Douglas Rizzo et al. Biology of Blood and Marrow Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Curtin United States	15	1.4k	1.1k	886	352	334	35	2.6k
Francesco Onida Italy	31	1.7k 1.2×	1.3k 1.2×	506 0.6×	411 1.2×	643 1.9×	118	3.0k
Nigel Westwood United Kingdom	21	913 0.7×	862 0.8×	767 0.9×	349 1.0×	480 1.4×	68	2.2k
Gian Matteo Rigolin Italy	30	831 0.6×	1.1k 1.1×	904 1.0×	693 2.0×	710 2.1×	117	2.8k
Mathias Schmid Germany	24	807 0.6×	638 0.6×	704 0.8×	233 0.7×	383 1.1×	86	2.0k
Fabı́ola Traina Brazil	28	1.3k 0.9×	909 0.9×	1.2k 1.4×	369 1.0×	282 0.8×	160	2.6k
George E. Georges United States	29	1.7k 1.2×	641 0.6×	597 0.7×	777 2.2×	585 1.8×	106	3.1k
Hélène A. Poirel Belgium	23	778 0.6×	637 0.6×	804 0.9×	351 1.0×	674 2.0×	56	2.1k
Marco Gabbianelli Italy	27	1.3k 0.9×	821 0.8×	1.4k 1.6×	520 1.5×	374 1.1×	68	2.7k
Detlef Haase Germany	23	2.4k 1.8×	1.1k 1.0×	1.0k 1.2×	235 0.7×	346 1.0×	101	3.1k
Toshiko Motoji Japan	26	1.5k 1.1×	700 0.7×	915 1.0×	399 1.1×	578 1.7×	121	2.6k

Countries citing papers authored by Peter Curtin

Since Specialization

Citations

This map shows the geographic impact of Peter Curtin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Curtin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Curtin more than expected).

Fields of papers citing papers by Peter Curtin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Curtin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Curtin. The network helps show where Peter Curtin may publish in the future.

Co-authorship network of co-authors of Peter Curtin

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Curtin. A scholar is included among the top collaborators of Peter Curtin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Curtin. Peter Curtin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jonas, Brian A., Peter Curtin, Gary J. Schiller, et al.. (2025). A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leukemia Research. 155. 107717–107717.

Shen, Guofang, et al.. (2023). Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring. Frontiers in Pharmacology. 14. 1126981–1126981. 11 indexed citations

Curtin, Peter, et al.. (2020). Comparison of Surgical Smoke Generated During Electrosurgery with Aerosolized Particulates from Ultrasonic and High-Speed Cutting. Annals of Biomedical Engineering. 49(2). 560–572. 9 indexed citations

Wieduwilt, Matthew J., Brian A. Jonas, Gary J. Schiller, et al.. (2018). A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. Blood. 132(Supplement 1). 4018–4018. 5 indexed citations

Jonas, Brian A., Peter Curtin, Gary J. Schiller, et al.. (2018). A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503. Blood. 132(Supplement 1). 3088–3088. 4 indexed citations

Broome, H. Elizabeth, et al.. (2015). Successful treatment of both double minute of C-MYC and BCL-2 rearrangement containing large B-cell lymphoma with subsequent unfortunate development of therapy-related acute myeloid leukemia with t(3;3)(q26.2;q21). Pathology - Research and Practice. 211(11). 883–891. 2 indexed citations

Curtin, Peter, et al.. (2014). Implementing inpatient, evidence-based, antihistamine-transfusion premedication guidelines at a single academic US hospital. The Journal of Community and Supportive Oncology. 12(2). 56–64. 5 indexed citations

Brammer, Jonathan E., James Gajewski, Peter Curtin, et al.. (2014). Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine, and Total Body Irradiation Conditioning Is Effective in an Elderly and Infirm Population. Biology of Blood and Marrow Transplantation. 21(1). 89–96. 6 indexed citations

Martin, Paul J., J. Douglas Rizzo, John R. Wingard, et al.. (2012). First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation. 18(8). 1150–1163. 423 indexed citations breakdown →

10.

Wang, Huan‐You, John Thorson, H. Elizabeth Broome, et al.. (2011). t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia. Human Pathology. 42(12). 2029–2036. 5 indexed citations

11.

Raza, Azra, Naomi Galili, Natalie S. Callander, et al.. (2009). Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. Journal of Hematology & Oncology. 2(1). 20–20. 49 indexed citations

12.

Laport, Ginna G., Brenda M. Sandmaier, Barry E. Storer, et al.. (2008). Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders. Biology of Blood and Marrow Transplantation. 14(2). 246–255. 97 indexed citations

13.

Kovacsovics, Tibor, Brandon Hayes‐Lattin, Peter Curtin, et al.. (2007). 257: Validation of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after matched unrelated donor SCT. Biology of Blood and Marrow Transplantation. 13(2). 94–94. 3 indexed citations

14.

Lazarus, Hillard M., Omer N. Koç, Steven M. Devine, et al.. (2005). Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients. Biology of Blood and Marrow Transplantation. 11(5). 389–398. 607 indexed citations breakdown →

15.

Leis, José F., Daniel E. Stepan, Peter Curtin, et al.. (2003). Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571). Leukemia & lymphoma. 45(4). 695–698. 82 indexed citations

16.

Madan, Ashima, et al.. (2003). Autocrine stimulation by erythropoietin in transgenic mice results in erythroid proliferation without neoplastic transformation☆☆Supported in part by National Institutes of Health Grants KO8 HL02966 (A.M.) and R29 DK44956 (P.T.C.) and by a Medical Research Foundation of Oregon grant (P.T.C.).. Blood Cells Molecules and Diseases. 30(1). 82–89. 9 indexed citations

17.

Emery, Sean, William B. Capra, David A. Cooper, et al.. (2000). Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin‐2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease. The Journal of Infectious Diseases. 182(2). 428–434. 86 indexed citations

18.

Rubin, Edward M., H. Ewa Witkowska, Elizabeth A. Spangler, et al.. (1991). Hypoxia-induced in vivo sickling of transgenic mouse red cells.. Journal of Clinical Investigation. 87(2). 639–647. 49 indexed citations

19.

Curtin, Peter & Yuet Wai Kan. (1989). The Molecular Genetics of Hemoglobin^a. Annals of the New York Academy of Sciences. 565(1). 1–12. 2 indexed citations

20.

Curtin, Peter, et al.. (1985). A distant gene deletion affects beta-globin gene function in an atypical gamma delta beta-thalassemia.. Journal of Clinical Investigation. 76(4). 1554–1558. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact